Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with acute myeloid leukemia (AML, but not the subtype called acute promyelocytic leukemia), confirmed through standard lab and genetic testing using 2022 diagnostic guidelines
• People aged 18 to 70 years old, of any gender
• People who have not yet received any treatment for AML (a short course of a medication like hydroxyurea to control white blood cell counts during diagnosis is allowed)
• People who have been assessed by a doctor as being able to tolerate intensive chemotherapy, based on a specific medical assessment framework
• People whose general physical functioning is rated at a certain level (a score of 2 or below on a standard medical scale, meaning they are able to care for themselves but may not be able to do heavy physical work)
• People whose kidney function test results fall within acceptable ranges for this trial
• People whose liver function test results fall within acceptable ranges for this trial
• People whose heart pumping function is at or above a minimum level (45% or within normal range, as measured by an ultrasound of the heart)
• People whose life expectancy is estimated to be more than 3 months

Who may not be able to join:

• People who have a history of certain blood or bone marrow conditions, including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, or a specific subtype of AML linked to a particular gene change (BCR-ABL1)
• People who have previously been treated with venetoclax or azacitidine for any condition
• People who have a known allergy or sensitivity to any ingredient in the trial medications
• People who have been diagnosed with another cancer within the past 2 years, with some exceptions — certain early-stage or fully treated skin cancers, cervical or breast carcinoma in situ, or cancers previously treated with curative surgery or similar methods may still be considered eligible (confirm with trial site)
• People who have a severe infection that is not under control, or who have active uncontrolled bleeding
• People who are pregnant or currently breastfeeding
• People who have an active, uncontrolled infection with HIV, hepatitis B, or hepatitis C
• People who show signs of leukemia that has spread to the brain or spinal fluid before treatment begins
• People of childbearing potential who are not willing to use at least one reliable form of contraception from the start of the trial until 90 days after the last dose, and male participants who are not willing to use contraception or to avoid donating sperm during the same period
• People who have epilepsy requiring ongoing medication, dementia, or other significant mental health conditions that would affect their ability to understand or follow the trial requirements
• People with psychiatric conditions or thinking difficulties that would prevent them from cooperating with treatment and follow-up, or conditions that prevent them from swallowing tablets or absorbing medication through the gut

Important: Always verify eligibility with the trial site directly before applying.